Form 4: Teva Pharmaceutical Director Sol Barer Reports Significant Share Ownership Changes and New RSU Grant

Teva Pharmaceutical Industries Ltd. Director Sol J. Barer reported the vesting of previously granted restricted share units and the acquisition of new units, alongside a disposition of ordinary shares.

Summary

• Sol J. Barer, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), filed a Form 4 detailing changes in his beneficial ownership.
• On June 6, 2025, 17,158 Restricted Share Units (RSUs) granted on June 6, 2024, vested and converted into ordinary shares.
• Following the vesting, 17,158 ordinary shares were disposed of, resulting in a beneficial ownership of 426,272 ordinary shares.
• On June 5, 2025, Mr. Barer acquired 21,739 new Restricted Share Units, which are scheduled to vest on June 5, 2026.
• Each restricted share unit represents a contingent right to receive one ordinary share or its cash equivalent at the option of the Human Resources and Compensation Committee.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects ongoing director compensation and retention through new RSU grants, despite a disposition of shares which is common post-vesting for tax or liquidity purposes.

Positives

• The vesting of 17,158 Restricted Share Units indicates the fulfillment of a prior compensation agreement, reflecting past performance or retention.
• The grant of 21,739 new Restricted Share Units demonstrates continued compensation for the director and aligns his future interests with the company's performance through future vesting.

Negatives

• The disposition of 17,158 ordinary shares, while potentially for tax withholding purposes, represents a reduction in the director's direct shareholding following the RSU vesting.

Future Outlook

The grant of new Restricted Share Units indicates a future vesting event on June 5, 2026, which will result in additional ordinary shares or their cash equivalent for the director.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide broader industry context. It reflects standard equity compensation practices for directors in publicly traded pharmaceutical companies.

Stakeholder Impact

• Shareholders: The report provides transparency regarding changes in a director's beneficial ownership, which can influence perceptions of insider alignment.
• Employees: The RSU grants reflect standard equity compensation practices, which are part of overall compensation strategies for key personnel.

Next Steps

• The 21,739 Restricted Share Units granted on June 5, 2025, are expected to vest on June 5, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC filing, insider transaction, beneficial ownership, restricted share units, RSU, director, Sol J. Barer, equity compensation